Login/Register

News

Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery

The total deal package, including upfront payment and development and sales milestones, has a value of $86 million dollars, with additional considerations throughout the term of the agreement.

Read more
Aug 17, 2023
Press release
Aug 16, 2023
Taipei Times
Aug 16, 2023
China Daily News
Aug 15, 2023
Commercial Times
Aug 11, 2023
Economic Daily
Aug 11, 2023
Lotus Pharmaceutical
Aug 10, 2023
China Times
Aug 09, 2023
Acepodia
Aug 08, 2023
BioSpectrum Asia